top of page
Image by Warren Umoh
Screenshot 2024-09-15 at 19.19.40.png
image.png

GENOUS™ SUCCESS STORY

Long-Term Disease Control in a 62-Year-Old Male with Cholangiocarcinoma

THE CHALLENGE

Cholangiocarcinoma is notoriously difficult to treat, and the patient’s tumor harbored an ERBB2 mutation, which suggested that standard therapies might not be sufficient. The challenge was to identify a targeted therapy that could effectively manage this mutation-driven cancer.

At 62, this man’s world was turned upside down when he was diagnosed with cholangiocarcinoma, a rare and aggressive cancer of the bile ducts. The initial treatment with cisplatin and gemcitabine, the standard for this cancer, was not enough to stop the  progression.

Screenshot 2024-09-15 at 19.19.57.png

THE PRECISION ONCOLOGY SOLUTION

The treating team conducted a comprehensive genetic analysis on a tumor tissue biopsy. This analysis revealed an ERBB2 mutation, a key driver of the cancer’s growth. Genomate® analyzed the molecular profile and suggested several potential targeted therapies. Among these, Afatinib, an ERBB2 inhibitor, and Bevacizumab, an angiogenesis inhibitor, emerged as the most promising combination. Armed with this, the molecular tumor board team recommended this personalized, off-label treatment strategy, tailoring the treatment specifically to his tumor.

THE RIGHT DRUG. THE FIRST TIME. EVERYTIME

The patient’s response to the combination therapy of Afatinib and Bevacizumab was outstanding, resulting in long-term disease control and significantly improving his quality of life.
For the treating team  it translated into:

  • Higher success rate

  • Faster decision making

  • Eliminating the guesswork and side effects

  • Giving the patient the best fighting chance

OUTCOME AND IMPACT OF TARGETED THERAPY

bottom of page